Evidence map›Paper›PMID 27226551›Full record

ArticleThe Journal of biological chemistry2016

Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.

Takafumi Mashiko, Eiji Sakashita, Katsumi Kasashima, Kaoru Tominaga, Kenji Kuroiwa, Yasuyuki Nozaki, Tohru Matsuura, Toshiro Hamamoto, Hitoshi Endo

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 44 citations in OpenAlex.

  1. RBM45 Preferential Binding to mThe journal of physical chemistry. B · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. RBM45 is an mCell reports · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Takafumi MashikoFrom the Departments of Biochemistry and Division of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan.
Eiji SakashitaFrom the Departments of Biochemistry and.
Katsumi KasashimaFrom the Departments of Biochemistry and.
Kaoru TominagaFrom the Departments of Biochemistry and.
Kenji KuroiwaFrom the Departments of Biochemistry and.
Yasuyuki NozakiPediatrics and.
Tohru MatsuuraDivision of Neurology, Department of Internal Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan.
Toshiro HamamotoFrom the Departments of Biochemistry and.
Hitoshi EndoFrom the Departments of Biochemistry and hendo@jichi.ac.jp.
Jichi Medical University · JPPediatrics and Genetics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytoplasmic protein aggregates are one of the pathological hallmarks of neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Several RNA-binding proteins have been identified as components of inclusion bodies. Developmentally regulated RNA-binding protein 1 (Drb1)/RNA-binding motif protein 45 is an RNA-binding protein that was recently described as a component in ALS- and FTLD-related inclusion bodies. However, the molecular mechanism underlying cytoplasmic Drb1 aggregation remains unclear. Here, using an in vitro cellular model, we demonstrated that Drb1 co-localizes with cytoplasmic aggregates mediated by TAR DNA-binding protein 43, a major component of ALS and FTLD-related inclusion bodies. We also defined the domains involved in the subcellular localization of Drb1 to clarify the role of Drb1 in the formation of cytoplasmic aggregates in ALS and FTLD. Drb1 predominantly localized in the nucleus via a classical nuclear localization signal in its carboxyl terminus and is a shuttling protein between the nucleus and cytoplasm. Furthermore, we identify a double leucine motif serving as a nuclear export signal. The Drb1 mutant, presenting mutations in both nuclear localization signal and nuclear export signal, is prone to aggregate in the cytoplasm. The mutant Drb1-induced cytoplasmic aggregates not only recruit TAR DNA-binding protein 43 but also decrease the mitochondrial membrane potential. Taken together, these results indicate that perturbation of Drb1 nuclear-cytoplasmic trafficking induces toxic cytoplasmic aggregates, suggesting that mislocalization of Drb1 is involved in the cause of cytotoxicity in neuronal cells.

Indexed as

Active Transport, Cell NucleusAmino Acid SequenceAmyotrophic Lateral SclerosisDNA-Binding ProteinsFrontotemporal Lobar DegenerationHeLa CellsHumansInclusion BodiesMutant ProteinsNerve Tissue ProteinsNuclear Export SignalsNuclear Localization SignalsProtein Aggregation, PathologicalRecombinant Fusion ProteinsRNA-Binding ProteinsDNA-Binding ProteinsMutant ProteinsNerve Tissue ProteinsNuclear Export SignalsNuclear Localization SignalsRBM45 protein, humanRecombinant Fusion ProteinsRNA-Binding ProteinsTARDBP protein, humanALS (Lou Gehrig disease)cytoplasmic inclusion bodyfrontotemporal lobar degeneration (FTLD)neurodegenerative diseasenuclear-cytoplasmic traffickingprotein aggregationRNA binding proteinTAR DNA-binding protein 43 (TDP-43, TARDBP)

Identifiers

PMID27226551
PMCPMC4946918
OpenAlexW2380328354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.